Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR - Chng, Wee Joo; Goldschmidt, Hartmut; Dimopoulos, Meletios A. (Leukemia, 2017)
Published: 27 December 2016